Schizophrenia: from dopamine to glutamate and back.
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000378:metabolism / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D018698:Glutamic Acid / Q000378:metabolism; D051379:Mice; D010879:Piperazines / Q000627:therapeutic use; D010880:Piperidines / Q000737:chemistry / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D010880:Piperidines; D015363:Quinolones; C109513:OSU 6162; D018698:Glutamic Acid; D000068180:Aripiprazole; C026539:preclamol; C483720:pridopidine; D004298:Dopamine